SCHEMBL657165

SCHEMBL657165

Cc1nc2cc(C(=O)N3CCN(C)CC3)ccn2c1-c1ccnc(C2(c3ccc(C(=O)NO)cc3)CC2)n1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MKNK1 Q9BUB5 2/20 0.43
MKNK2 Q9HBH9 2/20 0.43
AKT1 P31749 2/20 0.36
AKT2 P31751 2/20 0.36
CSF1R P07333 1/20 0.35
HDAC1 Q13547 4/20 0.35
KDM1A O60341 1/20 0.35
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
PARP1 P09874 1/20 0.34
CDK2 P24941 2/20 0.34
CDK4 P11802 1/20 0.34
CCNE1 P24864 1/20 0.34
CDK1 P06493 1/20 0.34
HPGD P15428 1/20 0.34
TSHR P16473 1/20 0.34
CDK5 Q00535 1/20 0.34
CDK5R1 Q15078 1/20 0.34
ADAM17 P78536 1/20 0.33
RIPK1 Q13546 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL658769 0.89 MKNK1 (0.46) MKNK1MKNK2AKT1AKT2HDAC1
SCHEMBL3355385 0.88 HDAC1 (0.50) AKT1AKT2CSF1RHDAC1CDK2
SCHEMBL657967 0.88 AKT1 (0.42) AKT1AKT2HDAC1CDK2CDK4
SCHEMBL3356590 0.86 AKT1 (0.42) AKT1AKT2HDAC1CDK2CDK4
SCHEMBL3351854 0.85 HDAC4 (0.41) MKNK1MKNK2AKT1AKT2CSF1R
SCHEMBL700913 0.83 CDK2 (0.51) MKNK1MKNK2CSF1RHDAC1CDK2
SCHEMBL3352703 0.83 CCNE1 (0.36) AKT1AKT2HDAC1CDK2CDK4
SCHEMBL658869 0.83 HDAC1 (0.36) AKT1AKT2HDAC1KDM1ACDK2
SCHEMBL657630 0.83
SCHEMBL3357617 0.82 CCNE1 (0.40) AKT1AKT2HDAC1KDM1ACDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8198299-B2 Cycloalkylidene and heterocycloalkylidene inhibitor compounds GILEAD SCIENCES, INC. (US) 2012-06-12 US claimed
US-20120045412-A1 CYCLOALKYLIDENE AND HETEROCYCLOALKYLIDENE INHIBITOR COMPOUNDS GILEAD SCIENCES, INC. (US) 2012-02-23 US claimed
US-20100022543-A1 CYCLOALKYLIDENE AND HETEROCYCLOALKYLIDENE INHIBITOR COMPOUNDS GILEAD SCIENCES, INC. 2010-01-28 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120045412-A1 CYCLOALKYLIDENE AND HETEROCYCLOALKYLIDENE INHIBITOR COMPOUNDS HDAC1, HDAC11, HDAC2 MKNK1 714/4885MKNK2 539/4885AKT1 1338/4885
US-20100022543-A1 CYCLOALKYLIDENE AND HETEROCYCLOALKYLIDENE INHIBITOR COMPOUNDS HDAC1, HDAC11, HDAC2 MKNK1 714/4885MKNK2 539/4885AKT1 1338/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.